Navigation Links
Lamotrigine May Reduce Epilepsy Seizures
Date:10/16/2007

Adding it to existing regimen may help, researchers say

TUESDAY, Oct. 16 (HealthDay News) -- When taken once a day as an added therapy, the epilepsy drug lamotrigine is effective in controlling partial seizures, an international study finds.

The 239 participants, aged 13 and older, were recruited from the United States and several other countries. They were already taking one or two medications, but these did not fully control their partial seizures.

The patients received either lamotrigine in extended-release formula or a placebo for 19 weeks. They continued taking their other epilepsy medications.

Patients who had lamotrigine added to their therapy had 46 percent fewer seizures during the study, compared to 24 percent fewer seizures among patients taking the placebo. The study also found that 42 percent of the patients who took the drug had reduced seizure frequency by the end of the study, compared with 24 percent of those who took the placebo.

The study, published in the Oct. 16 issue of the journal Neurology, was sponsored and conducted by drug maker GlaxoSmithKline, which markets lamotrigine as Lamictal.

"This new once daily medication may be an important option for people with epilepsy that could significantly increase their compliance with prescribed treatment," study author Dr. Dean Naritoku, of Southern Illinois University in Springfield, said in a prepared statement.

Patients need to take their medication reliably and consistently in order to maintain stable blood levels of epilepsy drugs and good control of seizures.

"The more often people have to remember to take their medication each day, the more likely they are to miss a dose. Once-a-day dosing is more convenient for patients," Naritoku said.

More information

The Epilepsy Foundation has more about epilepsy medications.



-- Robert Preidt



SOURCE: American Academy of Neurology, news release, Oct. 15, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Epilepsy Drug Valproate and Lamotrigine Linked To Malformed Fetus
2. Stress reduces your immunity- startling but true!!!!!
3. Risk of Cancer can be reduced to 40% with a High Fiber Diet
4. Thirty minutes of work up per day reduces the risk of Diabetes
5. Vaccine Reduces antibiotic-resistant infections in Children
6. Drugs said to Reduce HIV Transmission to Baby
7. Mentally Demanding Jobs Found To Reduce The Risk Of Alzheimer’
8. Vitamin D Reduces Chances of Colon, Breast And Ovarian Cancers by 50%
9. Aspirin reduces deaths
10. Stop smoking and reduce weight
11. Statins reduce heart attacks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... ... 2017 , ... Two innovative companies are bringing to market ... is scientifically proven as well: ABAlife™. Euromed SA, a leading manufacturer of therapeutic ... with BioTherapeutics Inc. for patented technology for absiscic acid (ABA). , The ...
(Date:9/26/2017)... ... ... Founded as an independent institute in 1968, The Glenholme School ... In 2018, Glenholme will celebrate its first 50 years and set a course for ... show ponies, was generously donated by Jean White Van Sinderen to Devereux in 1968. ...
(Date:9/26/2017)... ... September 26, 2017 , ... The ... strategic and tactical plans for Pittcon 2018. As of July 1, Adrian C. ... with his named vice president, Charles Gardner, (ChemImage Corporation) and selected chairs. ...
(Date:9/26/2017)... ... 26, 2017 , ... “Childhood Memories of a Virginia Wanderer”: an entertaining ... them relive their own youth. “Childhood Memories of a Virginia Wanderer” is the creation ... for nine years. He received his BS from Idaho State University in Adult ...
(Date:9/26/2017)... , ... September 26, 2017 , ... Time out for ... a little boy's newfound understanding that even grownups make mistakes. “Time Out for Daddy” ... United States for her entire life and whose passion for children inspired her to ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... 6, 2017 Eli Lilly and Company (NYSE: ... new data for galcanezumab and lasmiditan, two investigational treatments ... Headache Society (IHC) taking place Sept. 7-10 in ... highlight new, long-term data from an open-label study evaluating ... (120 mg and 240 mg) for the prevention of ...
(Date:9/5/2017)... 2017  Xyntek Inc. has announced another milestone in their continued growth and ... meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 West Adams Street, Suite 1528, ... Xyntek's recently ... ...
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months ... Insight is pleased to announce the appointment of three ... Tammy Wynne , Dominic Jones-Phillips and ... industry. Tammy ... team of market access writers. She has over ten ...
Breaking Medicine Technology: